198 related articles for article (PubMed ID: 27461278)
1. Podocalyxin-like protein, linked to poor prognosis of pancreatic cancers, promotes cell invasion by binding to gelsolin.
Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Hanazaki K; Saibara T
Cancer Sci; 2016 Oct; 107(10):1430-1442. PubMed ID: 27461278
[TBL] [Abstract][Full Text] [Related]
2. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
3. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL.
Chijiiwa Y; Moriyama T; Ohuchida K; Nabae T; Ohtsuka T; Miyasaka Y; Fujita H; Maeyama R; Manabe T; Abe A; Mizuuchi Y; Oda Y; Mizumoto K; Nakamura M
Int J Oncol; 2016 Apr; 48(4):1688-700. PubMed ID: 26892887
[TBL] [Abstract][Full Text] [Related]
5. Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells.
Tsuboi M; Taniuchi K; Furihata M; Naganuma S; Kimura M; Watanabe R; Shimizu T; Saito M; Dabanaka K; Hanazaki K; Saibara T
Pancreatology; 2016; 16(5):905-16. PubMed ID: 27453460
[TBL] [Abstract][Full Text] [Related]
6. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
Yan Z; Ohuchida K; Zheng B; Okumura T; Takesue S; Nakayama H; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Oda Y; Hashizume M; Nakamura M
J Cancer Res Clin Oncol; 2019 May; 145(5):1147-1164. PubMed ID: 30770989
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like protein promotes gastric cancer progression through interacting with RUN and FYVE domain containing 1 protein.
Zhi Q; Chen H; Liu F; Han Y; Wan D; Xu Z; Kuang Y; Zhou J
Cancer Sci; 2019 Jan; 110(1):118-134. PubMed ID: 30407695
[TBL] [Abstract][Full Text] [Related]
8. RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell invasion.
Taniuchi K; Furihata M; Iwasaki S; Tanaka K; Shimizu T; Saito M; Saibara T
Int J Oncol; 2014 Jun; 44(6):1945-54. PubMed ID: 24728183
[TBL] [Abstract][Full Text] [Related]
9. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma.
Lin CW; Sun MS; Wu HC
Int J Oncol; 2014 Aug; 45(2):710-8. PubMed ID: 24821609
[TBL] [Abstract][Full Text] [Related]
10. Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells.
Larrucea S; Butta N; Arias-Salgado EG; Alonso-Martin S; Ayuso MS; Parrilla R
Exp Cell Res; 2008 Jun; 314(10):2004-15. PubMed ID: 18456258
[TBL] [Abstract][Full Text] [Related]
11. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
12. Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
Kusumoto H; Shintani Y; Kanzaki R; Kawamura T; Funaki S; Minami M; Nagatomo I; Morii E; Okumura M
Cancer Sci; 2017 Mar; 108(3):528-535. PubMed ID: 28004467
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin-like, targeted by miR-138, promotes colorectal cancer cell proliferation, migration, invasion and EMT.
Xu Y; Pan ZG; Shu L; Li QJ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8664-8674. PubMed ID: 30575907
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of PODXL/ITGB1 and BCL7B/ITGB1 accurately predicts unfavorable prognosis compared to the TNM staging system in postoperative pancreatic cancer patients.
Taniuchi K; Furihata M; Naganuma S; Sakaguchi M; Saibara T
PLoS One; 2019; 14(6):e0217920. PubMed ID: 31166991
[TBL] [Abstract][Full Text] [Related]
15. ARHGEF4 predicts poor prognosis and promotes cell invasion by influencing ERK1/2 and GSK-3α/β signaling in pancreatic cancer.
Taniuchi K; Furihata M; Naganuma S; Saibara T
Int J Oncol; 2018 Nov; 53(5):2224-2240. PubMed ID: 30226582
[TBL] [Abstract][Full Text] [Related]
16. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis.
Kayed H; Kleeff J; Keleg S; Felix K; Giese T; Berger MR; Büchler MW; Friess H
Cancer Lett; 2007 Jan; 245(1-2):171-83. PubMed ID: 16488077
[TBL] [Abstract][Full Text] [Related]
17. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
18. WAVE2 is associated with poor prognosis in pancreatic cancers and promotes cell motility and invasiveness via binding to ACTN4.
Taniuchi K; Furihata M; Naganuma S; Saibara T
Cancer Med; 2018 Nov; 7(11):5733-5751. PubMed ID: 30353690
[TBL] [Abstract][Full Text] [Related]
19. Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas.
Heby M; Karnevi E; Elebro J; Nodin B; Eberhard J; Saukkonen K; Hagström J; Mustonen H; Seppänen H; Haglund C; Jirström K; Larsson AH
Sci Rep; 2020 Jun; 10(1):10373. PubMed ID: 32587323
[TBL] [Abstract][Full Text] [Related]
20. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.
Yuan D; Chen H; Wang S; Liu F; Cheng Y; Fang J
Cancer Med; 2018 Oct; 7(10):5155-5166. PubMed ID: 30277651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
